Search
Lactose
go.drugbank.com/drugs/DB04465ApprovedInvestigationalWithdrawnA disaccharide of glucose and galactose in human and cow milk. It is used in pharmacy for tablets, in medicine as a nutrient, and in industry.
Categories: Compounds used in a research, industrial, or household settingARG098
go.drugbank.com/drugs/DB06338ExperimentalARG098 (anti-Fas IgM monoclonal antibody) was studied in a Phase I clinical trial in 2007 involving patients with rheumatoid arthritis.
Armodafinil
go.drugbank.com/drugs/DB06413ApprovedInvestigational(a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Candicidin
go.drugbank.com/drugs/DB01152ApprovedInvestigationalWithdrawnCandicidin is an antibiotic obtained from a streptomyces (Streptomyces griseus) and active against some fungi of the genus Candida (C. albicans).
Rexlemestrocel-L
go.drugbank.com/drugs/DB17606InvestigationalRexlemestrocel-L is an investigational human bone marrow-derived allogeneic mesenchymal precursor cell (MPC) product. … It is being investigated in various cardiac conditions, such as chronic heart failure and acute myocardial infarction.
Zeranol
go.drugbank.com/drugs/DB11478ExperimentalVet approvedZeranol is a non-steroidal estrogen agonist. It is a mycotoxin, derived from fungi in the Fusarium family, and may be found as a contaminant in fungus-infected crops. … It is 3-4x more potent as an estrogen agonist than the related compound zearalenone.
ATP
go.drugbank.com/drugs/DB00171InvestigationalNutraceuticalAn adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter.
Olmutinib
go.drugbank.com/drugs/DB13164InvestigationalOlmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer.
NP-50301
go.drugbank.com/drugs/DB05662ExperimentalNP-50301 is an ophthalmic therapeutic eye drop treating post-menopausal Dry Eye Syndrome (DES). It is being developed by Nascent Pharmaceuticals.
Laquinimod
go.drugbank.com/drugs/DB06685InvestigationalIt is currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod. … Laquinimod is an immunomodulator developed by Active Biotech and produced by Teva Pharmaceutical Industries.